Evidence map›Paper›PMID 38258479›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

OptiMo-LDLr: An Integrated In Silico Model with Enhanced Predictive Power for LDL Receptor Variants, Unraveling Hot Spot Pathogenic Residues.

Asier Larrea-Sebal, Iñaki Sasiain, Shifa Jebari-Benslaiman, Unai Galicia-Garcia, Kepa B Uribe, Asier Benito-Vicente, Irene Gracia-Rubio, Harbil Bediaga-Bañeres, Sonia Arrasate, Ana Cenarro and 3 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Asier Larrea-SebalBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.
Iñaki SasiainDepartment of Biochemistry and Molecular Biology, Universidad del País Vasco UPV/EHU, Leioa, Bizkaia, 48940, Spain.
Shifa Jebari-BenslaimanBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.
Unai Galicia-GarciaBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.
Kepa B UribeDepartment of Biochemistry and Molecular Biology, Universidad del País Vasco UPV/EHU, Leioa, Bizkaia, 48940, Spain.
Asier Benito-VicenteBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.
Irene Gracia-RubioLipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, CIBERCV, Universidad de Zaragoza, Zaragoza, 50009, Spain.
Harbil Bediaga-BañeresDepartment of Physical Chemistry, University of Basque Country UPV/EHU, Leioa, 48940, Spain.
Sonia ArrasateDepartment of Organic and Chemistry, University of the Basque Country UPV/EHU, Leioa, 48940, Spain.
Ana CenarroLipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, CIBERCV, Universidad de Zaragoza, Zaragoza, 50009, Spain.
Fernando CiveiraLipid Unit, Hospital Universitario Miguel Servet, IIS Aragon, CIBERCV, Universidad de Zaragoza, Zaragoza, 50009, Spain.
Humberto González-DíazBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.
Cesar MartínBiofisika Institute (UPV/EHU, CSIC), Barrio Sarriena s/n., Leioa, Bizkaia, 48940, Spain.ORCID 0000-0002-4087-8729
University of the Basque Country · ESUniversidad de Zaragoza · ESIkerbasque · ES

Funding

Euskal Herriko Unibertsitatea Margarita Salas Grant 2022Grupos Consolidados Gobierno Vasco 2021 449IT1720-22Hezkuntza, Hizkuntza Politika Eta Kultura Saila, Eusko Jaurlaritza grant PIF (2019-2020)Ministerio de Ciencia, Innovación y Universidades PID2022-136788OB-I00
6 · The paper itself

Abstract

Familial hypercholesterolemia (FH) is an inherited metabolic disease affecting cholesterol metabolism, with 90% of cases caused by mutations in the LDL receptor gene (LDLR), primarily missense mutations. This study aims to integrate six commonly used predictive software to create a new model for predicting LDLR mutation pathogenicity and mapping hot spot residues. Six predictive-software are selected: Polyphen-2, SIFT, MutationTaster, REVEL, VARITY, and MLb-LDLr. Software accuracy is tested with the characterized variants annotated in ClinVar and, by bioinformatic and machine learning techniques all models are integrated into a more accurate one. The resulting optimized model presents a specificity of 96.71% and a sensitivity of 98.36%. Hot spot residues with high potential of pathogenicity appear across all domains except for the signal peptide and the O-linked domain. In addition, translating this information into 3D structure of the LDLr highlights potentially pathogenic clusters within the different domains, which may be related to specific biological function. The results of this work provide a powerful tool to classify LDLR pathogenic variants. Moreover, an open-access guide user interface (OptiMo-LDLr) is provided to the scientific community. This study shows that combination of several predictive software results in a more accurate prediction to help clinicians in FH diagnosis.

Indexed as

Hyperlipoproteinemia Type IIComputer SimulationHumansMutationPhenotypeReceptors, LDLReceptors, LDLhot spotin silicoLDLrpredictive software

Identifiers

PMID38258479
PMCPMC10987110
OpenAlexW4391141802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.